LifeArc is a medical research charity with a 25-year legacy of helping scientists and organizations translate their research into treatments and diagnostics for patients.  LifeArc turns great science into greater patient impact.  The charity brings together a network of partners to tackle specific diseases and directly funds academic and early stage research.  So far, LifeArc’s work has helped to develop four approved medicines (Keytruda®, Actemra®, Tysabri® and Entyvio®) and a diagnostic test for resistance to carbapenem.

TAUC3 BIO collaborated with LifeArc to produce a humanize a monoclonal antibody (TBL-100) that targets C-terminally truncated tau (tauC3). The collaboration has produced a lead candidate for further development and several good backup molecules offering acombination of excellent biophysical characteristics, high affinity binding, high expression and thermostability properties.

Northwestern University

TAUC3 BIO has worldwide rights to the development and commercialization of the TBL-100 monoclonal antibody under an exclusive license from Northwestern University. The murine antibody was generated by the late Professor Lester Binder (1945-2013) who first discovered tauC3 and has often been referred to as the “the godfather of tau” because of his unmatched understanding of the intricate nuances of this protein and his many seminal contributions to the field.